表紙
市場調查報告書
商品編碼
1004982

全球Castleman病(CD)治療市場(2020年∼2027年)

Global Castleman Disease Treatment Market - 2022-2029

出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

Castleman病(CD)是一種發生在淋巴結和相關組織中的罕見疾病,由 Benjamin Castleman 博士在 1950 年代首次報導。巨大淋巴結增生,也稱為血管濾泡淋巴結增生(AFH)。這幾年,隨著HIV的感染者數的增加,多中心性Castleman病的診斷數也增加著。

本報告提供全球Castleman病(CD)治療市場調查市場調查,彙整市場概要,市場區隔·各地區的市場規模及成長率的變化與預測,新型冠狀病毒感染疾病(COVID-19)的影響分析,市場成長的推動要素及阻礙因素分析,市場機會,價格及貿易趨勢,競爭情形,主要企業簡介等資訊。

目錄

第1章 調查手法和範圍

  • 調查手法
  • 調查的目的和調查範圍

第2章 市場定義和概要

第3章 摘要整理

  • 市場明細:各治療類型
  • 市場明細:各終端用戶
  • 市場明細:各地區

第4章 市場動態

  • 市場影響要素
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 產業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價格分析
  • 法規分析
  • 償付分析
  • 未滿足需求

第6章 新型冠狀病毒感染疾病(COVID-19)的影響分析

  • 新型冠狀病毒感染疾病(COVID-19)的影響分析
    • COVID-19前的市場方案
    • 目前市場方案
    • COVID-19後的市場方案
  • COVID-19疫情下價格趨勢
  • 供需頻譜
  • 政府在COVID-19疫情下的市場相關措施
  • 製造商策略性舉措
  • 總論

第7章 全球Castleman病(CD)治療市場:各治療類型

  • 簡介
  • 市場規模·與前一年同期比較成長率分析:各治療類型
  • 市場魅力指數:各治療類型
    • 單株抗體
    • 化療
    • 外科手術
    • 放射治療
    • 皮質類固醇
    • 抗病毒藥物
    • 其他

第8章 全球Castleman病(CD)治療市場:各終端用戶

  • 簡介
  • 市場規模·與前一年同期比較成長率分析:各終端用戶
  • 市場魅力指數:各終端用戶
    • 醫院
    • 外科中心
    • 門診病人治療中心
    • 其他

第9章 全球Castleman病(CD)治療市場:各地區

  • 簡介
  • 市場規模分析·與前一年同期比較成長率:各地區
  • 市場魅力指數:各地區
  • 北美
    • 簡介
    • 市場動態
    • 市場規模·與前一年同期比較成長率:各治療類型
    • 市場規模·與前一年同期比較成長率:各終端用戶
    • 市場規模·與前一年同期比較成長率:各國
  • 歐洲
    • 簡介
    • 市場動態
    • 市場規模·與前一年同期比較成長率:各治療類型
    • 市場規模·與前一年同期比較成長率:各終端用戶
    • 市場規模·與前一年同期比較成長率:各國
  • 南美
    • 簡介
    • 市場動態
    • 市場規模·與前一年同期比較成長率:各治療類型
    • 市場規模·與前一年同期比較成長率:各終端用戶
    • 市場規模·與前一年同期比較成長率:各國
  • 亞太地區
    • 簡介
    • 市場動態
    • 市場規模·與前一年同期比較成長率:各治療類型
    • 市場規模·與前一年同期比較成長率:各終端用戶
    • 市場規模·與前一年同期比較成長率:各國
  • 中東·非洲
    • 簡介
    • 市場動態
    • 市場規模·與前一年同期比較成長率:各治療類型
    • 市場規模·與前一年同期比較成長率:各終端用戶
    • 市場規模·與前一年同期比較成長率:各國

第10章 競爭情形

  • 競爭模式
  • 市場定位/股票分析
  • 合併·收購分析

第11章 企業簡介

  • Johnson & Johnson Services Inc
    • 企業概要
    • 產品系列
    • 主要的焦點
    • 財務形勢
  • Hospira Inc,
  • F. Hoffmann-La Roche Ltd,
  • Cylene Pharma,
  • Pfizer Inc,
  • Merck & Co., Inc,
  • Novartis AG,
  • Bristol-Myers Squibb Company,
  • Incyte Corporation,
  • Jazz Pharmaceuticals, Inc.

第12章 重要考察

第13章 關於DataM Intelligence

目錄
Product Code: DMPH3381

Market Overview

The Global Castleman Disease Treatment Market is expected to grow at a high CAGR during the forecasting period (2022-2029).

Castleman disease is a rare disorder in which cells in the lymph nodes grow out of control. The most prevalent form of the disorder (unicentric Castleman disease) involves a single lymph node in the chest or belly. Depending on the patient's type of Castleman disease, treatment and prognosis will differ. Surgery is frequently successful in treating the type that involves only one lymph node.

Market Dynamics

Clinical trials conducted by the research institutes for the treatment of Castleman Disease are expected to drive market growth.

The Castleman Disease Collaborative Network (CDCN) has teamed up with the University of Pennsylvania and the University of Arkansas for Medical Sciences to conduct a study of sirolimus, an investigational medicine, for adults with idiopathic multicentric Castleman disease (iMCD) who have failed to respond to anti-IL-6 therapies. Siltuximab (Sylvant) and tocilizumab are two anti-IL-6 drugs (Actemra). Moreover, The Peking Union Medical College Hospital in Beijing, China, sought participants for a clinical trial examining the efficacy and safety of the drugs bortezomib, cyclophosphamide, and dexamethasone (BCD regimen). Thus, the market is expected to drive in the forecast period from the above statements.

Restraint:

Due to the disease's low prevalence rate and a lack of knowledge about it, there is a lack of awareness. The Patent expiry of several companies associated with the high cost of treatment are factors the market is expected to hamper in the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. Anti-IL6 drugs like siltuximab and tocilizumab are also being used to treat COVID-19-induced cytokine storms in some critically ill patients. Moreover, Anti-IL6 medicines like siltuximab and tocilizumab are now well-established as viable treatments for some individuals with idiopathic multicentric Castleman disease. These drugs alleviate symptoms in the short term, but they are also safe and provide long-term disease control in responders. During the COVID-19 pandemic, the CDCN understands a supply shortfall of siltuximab and tocilizumab. The CDCN is concerned about the availability of these important medications for Castleman Disease patients. The CDCN learned that the producers of siltuximab and tocilizumab are committed to providing the drugs to individuals with Castleman Disease. Therefore, many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.

Segment Analysis

Immunotherapy segment is expected to hold the largest market share in castleman disease treatment market

The immunotherapy segment is expected to dominate in 2021. The segment is benefitted because drugs like siltuximab (Sylvant) and rituximab (Rituxan) can inhibit the function of a protein that is overproduced in persons with multicentric Castleman disease. Moreover, medicines and other therapies to control cell overgrowth are commonly used to treat multicentric Castleman disease. Treatment options vary depending on the severity of your illness and whether the patient has HIV, HHV-8, or both. Therefore, these agents do not only control symptoms short-term but continued administration to responders is safe and provides durable disease control. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.

Geographical Analysis

North America region holds the largest market share in the global castleman disease treatment market

In 2021, North America accounted for the highest revenue share. The increasing prevalence of idiopathic multicentric Castleman disease (iMCD), well-established infrastructure, companies focusing on research & development and performing clinical trials and the presence of major players as well as government measures that aid medicine development for orphan diseases are some of the factors the market is expected to boost in the forecast period. For instance, it is estimated that 6500 to 7700 new cases are diagnosed each year in the United States; approximately 1000 of those are HHV-8-associated multicentric Castleman disease (HHV-8-associated MCD), and 1000 are HHV-8-negative MCD. Moreover, The Castleman Disease Collaborative Network (CDCN) has teamed up with the University of Pennsylvania and the University of Arkansas for Medical Sciences to conduct a study of sirolimus, an investigational medicine, for adults with idiopathic multicentric Castleman disease (iMCD) who have failed to respond to anti-IL-6 therapies. Siltuximab (Sylvant) and tocilizumab are two anti-IL-6 drugs (Actemra). Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Competitive Landscape

Major key players in the castleman disease treatment market are EUSA Pharma, Johnson & Johnson Services, Inc., Genentech USA, Inc., F. Hoffmann-La Roche Ltd, Amgen Inc., Bristol-Myers Squibb Company, Par Pharmaceutical, Exela Pharma Sciences.

EUSA Pharma:

Overview:

EUSA Pharma was founded in March 2006. It is a newly-established, profitable specialty pharmaceutical company with global reach from its UK headquarters and commercial operations across Europe and the USA. It is focused on oncology and rare disease, continuously striving to confront gaps in patient care. EUSA Pharma also has a wide distribution network of commercial partners in Europe, the Middle East, Asia and Latin America. It makes products available in approximately 40 countries worldwide through this broad international platform.

­Product Portfolio:

SYLVANT (siltuximab): It is the first and only FDA/EMA approved therapy for idiopathic Multicentric Castleman Disease (iMCD) and is recommended as the preferred first line therapy by clinical guidelines.

Why Purchase the Report?

Visualize the composition of the castleman disease treatment market segmentation by type, diagnosis, treatment, end user, distribution channel, and region highlighting the key commercial assets and players.

Identify commercial opportunities in castleman disease treatment market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of castleman disease treatment market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global castleman disease treatment market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market Snippet by Diagnosis
  • 3.3. Market Snippet by Treatment
  • 3.4. Market Snippet by End user
  • 3.5. Market Snippet by Distribution channel
  • 3.6. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Clinical trials conducted by the research institutes for the treatment of Castleman Disease are expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of treatment is expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Unicentric Castleman disease*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Multicentric Castleman disease

8. By Diagnosis

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 8.1.2. Market Attractiveness Index, By Diagnosis Segment
  • 8.2. Blood and urine tests*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Imaging tests
    • 8.3.1. X-rays
    • 8.3.2. CT Scans
    • 8.3.3. Others
  • 8.4. Lymph node biopsy
  • 8.5. Others

9. By Treatment

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 9.1.2. Market Attractiveness Index, By Treatment Segment
  • 9.2. Immunotherapy*
    • 9.2.1. Siltuximab (Sylvant)
    • 9.2.2. Rituximab (Rituxan)
    • 9.2.3. Others
    • 9.2.4. Introduction
    • 9.2.5. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Chemotherapy
  • 9.4. Corticosteroids
    • 9.4.1. Prednisone
    • 9.4.2. Tocilizumab
    • 9.4.3. Lenalidomide
    • 9.4.4. Glucocorticoids
    • 9.4.5. Others
  • 9.5. Antiviral drugs
    • 9.5.1. Ganciclovir
    • 9.5.2. Others

10. By End user

    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.1.2. Market Attractiveness Index, By End user Segment
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Clinics
  • 10.4. Ambulatory Surgical Centers
  • 10.5. Diagnostic Centers
  • 10.6. Others

11. By Distribution Channel

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 11.2. Hospital Pharmacies*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 11.3. Retail Pharmacies
  • 11.4. Online Pharmacies
  • 11.5. Others

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.2.8.1. U.S.
      • 12.2.8.2. Canada
      • 12.2.8.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.3.8.1. Germany
      • 12.3.8.2. U.K.
      • 12.3.8.3. France
      • 12.3.8.4. Italy
      • 12.3.8.5. Spain
      • 12.3.8.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.4.8.1. Brazil
      • 12.4.8.2. Argentina
      • 12.4.8.3. Rest of South America
  • 12.5. Asia Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.5.8.1. China
      • 12.5.8.2. India
      • 12.5.8.3. Japan
      • 12.5.8.4. Australia
      • 12.5.8.5. Rest of Asia Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

  • 13.1. Key Developments and Strategies
  • 13.2. Company Share Analysis
  • 13.3. Product Benchmarking
  • 13.4. List of Key Companies to Watch

14. Company Profiles

  • 14.1. EUSA Pharma*
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Key Highlights
    • 14.1.4. Financial Overview
  • 14.2. Johnson & Johnson Services, Inc.
  • 14.3. Genentech USA, Inc.
  • 14.4. F. Hoffmann-La Roche Ltd
  • 14.5. Amgen Inc.
  • 14.6. Bristol-Myers Squibb Company
  • 14.7. Par Pharmaceutical
  • 14.8. Exela Pharma Sciences

LIST NOT EXHAUSTIVE

15. Global Castleman Disease Treatment Market - DataM

  • 15.1. Appendix
  • 15.2. About Us and Applications
  • 15.3. Contact Us